Interactions between Lactitol and VESIcare
1 drug interaction and 9 additional warnings found for the following 2 drugs:
- lactitol
- VESIcare (solifenacin)
Drug interactions
Moderate drug interactions
Moderate:
solifenacin lactitol
Applies to: VESIcare (solifenacin) and lactitol
Monitor
Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.
Management
Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients treated with lactulose for more than six months should be monitored periodically for electrolyte imbalance. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
References (4)
- Chin RL (1998) "Laxative-induced hypokalemia." Ann Emerg Med, 32, p. 517-8
- Muller-Lissner SA (1993) "Adverse effects of laxatives: fact and fiction." Pharmacology, 47, p. 138-45
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Schaefer DC, Cheskin LJ (1998) "Constipation in the elderly." Am Fam Physician, 58, p. 907-14
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
lactitol Food/Lifestyle
Applies to: lactitol
Adjust dosing interval
Lactitol may decrease the absorption of concomitantly administered oral medications.
Management
Lactitol should be administered at least 2 hours before or 2 hours after concomitant oral medications.
References (1)
- (2020) "Product Information. Pizensy (lactitol)." Braintree Laboratories
Disease interactions
8 potential interactions Applies to: 8 conditions, including Dementia, Urinary Retention, Liver Disease, Long QT Syndrome, and Renal Dysfunction.
Central Nervous System Disorders
Moderate:
VESIcare
The solifenacin in VESIcare has a moderate potential interaction with Central Nervous System Disorders.
Solifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Solifenacin should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.
Dementia
Moderate:
VESIcare
The solifenacin in VESIcare has a moderate potential interaction with Dementia.
Solifenacin is associated with anticholinergic central nervous system (CNS) effects. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered. Solifenacin should be used with caution in patients with Parkinson's disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.
Gastrointestinal Obstruction
Major:
VESIcare
The solifenacin in VESIcare has a major potential interaction with Gastrointestinal Obstruction.
The use of solifenacin is contraindicated in patients with gastric retention. Caution is advised even when using this agent in patients with decreased gastrointestinal motility.
Glaucoma, Narrow Angle
Major:
VESIcare
The solifenacin in VESIcare has a major potential interaction with Glaucoma, Narrow Angle.
The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma. Caution is advised even when using this agent in patients with narrow-angle glaucoma.
Liver Disease
Major:
VESIcare
The solifenacin in VESIcare has a major potential interaction with Liver Disease.
Solifenacin should be used with caution in patients with reduced hepatic function. Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment. Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer. Solifenacin is not recommended in patients with severe hepatic impairment. .
Long QT Syndrome
Moderate:
VESIcare
The solifenacin in VESIcare has a moderate potential interaction with Long QT Syndrome.
Dose dependent prolongation in QT interval has been observed with the use of solifenacin. This drug should be used with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.
Renal Dysfunction
Major:
VESIcare
The solifenacin in VESIcare has a major potential interaction with Renal Dysfunction.
Solifenacin should be used with caution in patients with renal impairment. Increase in half-life and AUC have been demonstrated in patients with severe renal impairment. Caution should be taken when prescribing this agent to patients with renal impairment. Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.
Urinary Retention
Major:
VESIcare
The solifenacin in VESIcare has a major potential interaction with Urinary Retention.
The use of solifenacin is contraindicated in patients with urinary retention. Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.
Report options
More resources
lactitol
A total of 239 drugs are known to interact with lactitol.
- Lactitol is in the drug class laxatives.
- Lactitol is used to treat Chronic Idiopathic Constipation.
VESIcare
A total of 530 drugs are known to interact with VESIcare.
- Vesicare is in the drug class urinary antispasmodics.
- Vesicare is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.